Opioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk management

References

• PergolizziJVJrMaLFosterDRThe prevalence of opioid-related major potential drug-drug interactions and their impact on health care costs in chronic pain patientsJ Manag Care Spec Pharm201420546747624761818
   PubMed Web of Science ®Google Scholar
• SummersKHPuenpatomRARajanNBen-JosephROhsfeldtREconomic impact of potential drug-drug interactions in opioid analgesicsJ Med Econ201114439039621574905
   PubMedGoogle Scholar
• AkobengAKUnderstanding randomised controlled trialsArch Dis Child200590884084416040885
   PubMed Web of Science ®Google Scholar
• Kotlinska-LemieszekAKlepstadPHaugenDFClinically significant drug-drug interactions involving opioid analgesics used for pain treatment in patients with cancer: a systematic reviewDrug Des Devel Ther2015952555267
   PubMed Web of Science ®Google Scholar
• OverholserBRFosterDROpioid pharmacokinetic drug-drug interactionsAm J Manag Care201117Suppl 11S276S28721999760
   PubMedGoogle Scholar
• GharaviRHedrichWWangHHassanHETransporter-mediated disposition of opioids: implications for clinical drug interactionsPharm Res20153282477250225972096
   PubMed Web of Science ®Google Scholar
• MercadanteSOpioid metabolism and clinical aspectsEur J Pharmacol2015769717826522929
   PubMed Web of Science ®Google Scholar
• MercerSLCoopAOpioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic toleranceCurr Top Med Chem20111191157116421050174
   PubMed Web of Science ®Google Scholar
• KharaschEDHofferCWhittingtonDSheffelsPRole of P-glycoprotein in the intestinal absorption and clinical effects of morphineClin Pharmacol Ther200374654355414663457
   PubMed Web of Science ®Google Scholar
• ParkHJShinnHKRyuSHLeeHSParkCSKangJHGenetic polymorphisms in the ABCB1 gene and the effects of fentanyl in KoreansClin Pharmacol Ther200781453954617192767
   PubMed Web of Science ®Google Scholar
• ZwislerSTEnggaardTPNoehr-JensenLThe antinociceptive effect and adverse drug reactions of oxycodone in human experimental pain in relation to genetic variations in the OPRM1 and ABCB1 genesFundam Clin Pharmacol201024451752419845769
   PubMed Web of Science ®Google Scholar
• TzvetkovMVdos Santos PereiraJNMeinekeISaadatmandARStinglJCBrockmöllerJMorphine is a substrate of the organic cation transporter OCT1 and polymorphisms in OCT1 gene affect morphine pharmacokinetics after codeine administrationBiochem Pharmacol201386566667823835420
   PubMed Web of Science ®Google Scholar
• TzvetkovMVSaadatmandARLötschJTegederIStinglJCBrockmöllerJGenetically polymorphic OCT1: another piece in the puzzle of the variable pharmacokinetics and pharmacodynamics of the opioidergic drug tramadolClin Pharmacol Ther201190114315021562485
   PubMed Web of Science ®Google Scholar
• LiWZengSYuLSZhouQPharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk managementTher Clin Risk Manag2013925927123745048
   PubMed Web of Science ®Google Scholar
• HoblELStimpflTEbnerJMorphine decreases clopidogrel concentrations and effects: a randomized, double-blind, placebo-controlled trialJ Am Coll Cardiol201463763063524315907
   PubMed Web of Science ®Google Scholar
• HoblELReiterBSchoergenhoferCMorphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteersClin Res Cardiol2016105434935526493304
   PubMed Web of Science ®Google Scholar
• HoblELReiterBSchoergenhoferCMorphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteersEur J Clin Invest201646171426449338
   PubMed Web of Science ®Google Scholar
• KubicaJAdamskiPOstrowskaMMorphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trialEur Heart J201637324525226491112
   PubMed Web of Science ®Google Scholar
• KubicaJKubicaAJilmaBImpact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitorsInt J Cardiol201621520120827128531
   PubMed Web of Science ®Google Scholar
• TengRCarlsonGHsiaJAn open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteersInt J Clin Pharmacol Ther201553218218925500486
   PubMed Web of Science ®Google Scholar
• EckhardtKAmmonSHofmannURiebeAGugelerNMikusGGabapentin enhances the analgesic effect of morphine in healthy volunteersAnesth Analg200091118519110866910
   PubMed Web of Science ®Google Scholar
• ChenCUpwardJArumughamTStierBDavyMGabapentin enacarbil and morphine administered in combination versus alone: a double-blind, randomized, pharmacokinetic, and tolerability comparisonClin Ther201537234935725467190
   PubMed Web of Science ®Google Scholar
• McCance-KatzEFRaineyPMJatlowPFriedlandGMethadone effects on zidovudine disposition (AIDS Clinical Trials Group 262)J Acquir Immune Defic Syndr Hum Retrovirol19981854354439715839
   PubMedGoogle Scholar
• McCance-KatzEFRaineyPMFriedlandGKostenTRJatlowPEffect of opioid dependence pharmacotherapies on zidovudine dispositionAm J Addict200110429630711783744
   PubMed Web of Science ®Google Scholar
• FrommMFEckhardtKLiSLoss of analgesic effect of morphine due to coadministration of rifampinPain1997721–22612679272811
   PubMed Web of Science ®Google Scholar
• FudinJFontenelleDVPayneARifampin reduces oral morphine absorption: a case of transdermal buprenorphine selection based on morphine pharmacokineticsJ Pain Palliat Care Pharmacother201226436236723216174
   PubMedGoogle Scholar
• SaarikoskiTSaariTIHagelbergNMRifampicin markedly decreases the exposure to oral and intravenous tramadolEur J Clin Pharmacol20136961293130123242004
   PubMed Web of Science ®Google Scholar
• NieminenTHHagelbergNMSaariTIRifampin greatly reduces the plasma concentrations of intravenous and oral oxycodoneAnesthesiology200911061371137819417618
   PubMed Web of Science ®Google Scholar
• KharaschEDHofferCWhittingtonDSheffelsPRole of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadoneClin Pharmacol Ther200476325026915371986
   PubMed Web of Science ®Google Scholar
• BrownLSSawyerRCLiRCobbMNColbornDCNarangPKLack of a pharmacologic interaction between rifabutin and methadone in HIV-infected former injecting drug usersDrug Alcohol Depend1996431–271778957145
   PubMed Web of Science ®Google Scholar
• McCance-KatzEFMoodyDEPrathikantiSFriedlandGRaineyPMRifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patientsDrug Alcohol Depend20111182–332633421596492
   PubMed Web of Science ®Google Scholar
• KharaschEDHofferCAltuntasTGWhittingtonDQuinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanylJ Clin Pharmacol200444322423314973303
   PubMed Web of Science ®Google Scholar
• HeiskanenTOlkkolaKTKalsoEEffects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodoneClin Pharmacol Ther19986466036119871425
   PubMed Web of Science ®Google Scholar
• SamerCFDaaliYWagnerMThe effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodoneBr J Pharmacol2010160490791820590587
   PubMed Web of Science ®Google Scholar
• CaracoYShellerJWoodAJImpact of ethnic origin and quinidine coadministration on codeine’s disposition and pharmacodynamic effectsJ Pharmacol Exp Ther1999290141342210381807
   PubMed Web of Science ®Google Scholar
• KathiramalainathanKKaplanHLRomachMKInhibition of cytochrome P450 2D6 modifies codeine abuse liabilityJ Clin Psychopharmacol200020443544410917405
   PubMed Web of Science ®Google Scholar
• Wilder-SmithCHHufschmidEThormannWThe visceral and somatic antinociceptive effects of dihydrocodeine and its metabolite, dihydromorphine. A cross-over study with extensive and quinidine-induced poor metabolizersBr J Clin Pharmacol19984565755819663813
   PubMed Web of Science ®Google Scholar
• KharaschEDHofferCWhittingtonDThe effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadoneBr J Clin Pharmacol200457560061015089813
   PubMed Web of Science ®Google Scholar
• FihlmanMHemmiläTHagelbergNMVoriconazole more likely than posaconazole increases plasma exposure to sublingual buprenorphine causing a risk of a clinically important interactionEur J Clin Pharmacol201672111363137127510521
   PubMed Web of Science ®Google Scholar
• KapilRPCiprianoAMichelsGHEffect of ketoconazole on the pharmacokinetic profile of buprenorphine following administration of a once-weekly buprenorphine transdermal systemClin Drug Investig2012329583592
   PubMed Web of Science ®Google Scholar
• SaariTILaineKNeuvonenMNeuvonenPJOlkkolaKTEffect of voriconazole and fluconazole on the pharmacokinetics of intravenous fentanylEur J Clin Pharmacol2008641253017987285
   PubMed Web of Science ®Google Scholar
• ZiesenitzVCKönigSKMahlkeNSSkoppGHaefeliWEMikusGPharmacokinetic interaction of intravenous fentanyl with ketoconazoleJ Clin Pharmacol201555670871725651378
   PubMed Web of Science ®Google Scholar
• PalkamaVJNeuvonenPJOlkkolaKTThe CYP 3A4 inhibitor itraconazole has no effect on the pharmacokinetics of i.v. fentanylBr J Anaesth19988145986009924238
   PubMed Web of Science ®Google Scholar
• HeiskanenTBackmanJTNeuvonenMKontinenVKNeuvonenPJKalsoEItraconazole, a potent inhibitor of P-glycoprotein, moderately increases plasma concentrations of oral morphineActa Anaesthesiol Scand200852101319132619025521
   PubMed Web of Science ®Google Scholar
• GrönlundJSaariTIHagelbergNNeuvonenPJOlkkolaKTLaineKMiconazole oral gel increases exposure to oral oxycodone by inhibition of CYP2D6 and CYP3A4Antimicrob Agents Chemother20115531063106721173180
   PubMed Web of Science ®Google Scholar
• HagelbergNMNieminenTHSaariTIVoriconazole drastically increases exposure to oral oxycodoneEur J Clin Pharmacol200965326327118836708
   PubMed Web of Science ®Google Scholar
• LiuPFosterGLabadieRSomozaESharmaAPharmacokinetic interaction between voriconazole and methadone at steady state in patients on methadone therapyAntimicrob Agents Chemother200751111011817074798
   PubMed Web of Science ®Google Scholar
• CobbMNDesaiJBrownLSJrZannikosPNRaineyPMThe effect of fluconazole on the clinical pharmacokinetics of methadoneClin Pharmacol Ther19986366556629663180
   PubMed Web of Science ®Google Scholar
• GrünBKrautterSRiedelKDMikusGInhibition of the active principle of the weak opioid tilidine by the triazole antifungal voriconazoleBr J Clin Pharmacol200968571272019916995
   PubMed Web of Science ®Google Scholar
• SaarikoskiTSaariTIHagelbergNMEffects of terbinafine and itraconazole on the pharmacokinetics of orally administered tramadolEur J Clin Pharmacol201571332132725560051
   PubMed Web of Science ®Google Scholar
• NieminenTHHagelbergNMSaariTIOxycodone concentrations are greatly increased by the concomitant use of ritonavir or lopinavir/ritonavirEur J Clin Pharmacol2010661097798520697700
   PubMed Web of Science ®Google Scholar
• OlkkolaKTPalkamaVJNeuvonenPJRitonavir’s role in reducing fentanyl clearance and prolonging its half-lifeAnesthesiology199991368168510485779
   PubMed Web of Science ®Google Scholar
• GrünBMerkelURiedelKDWeissJMikusGContribution of CYP2C19 and CYP3A4 to the formation of the active nortilidine from the prodrug tilidineBr J Clin Pharmacol201274585486322381043
   PubMed Web of Science ®Google Scholar
• NieminenTHHagelbergNMSaariTIGrapefruit juice enhances the exposure to oral oxycodoneBasic Clin Pharmacol Toxicol2010107478278820406214
   PubMed Web of Science ®Google Scholar
• KharaschEDWhittingtonDHofferCInfluence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrateAnesthesiology2004101372973715329598
   PubMed Web of Science ®Google Scholar
• NielsenAGPedersenRSNoehr-JensenLDamkierPBrosenKTwo separate dose-dependent effects of paroxetine: mydriasis and inhibition of tramadol’s O-demethylation via CYP2D6Eur J Clin Pharmacol201066765566020354688
   PubMed Web of Science ®Google Scholar
• LaugesenSEnggaardTPPedersenRSSindrupSHBrøsenKParoxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadolClin Pharmacol Ther200577431232315903129
   PubMed Web of Science ®Google Scholar
• KapilRPFriedmanKCiprianoAEffects of paroxetine, a CYP2D6 inhibitor, on the pharmacokinetic properties of hydrocodone after coadministration with a single-entity, once-daily, extended-release hydrocodone tabletClin Ther201537102286229626350273
   PubMed Web of Science ®Google Scholar
• GrönlundJSaariTIHagelbergNMNeuvonenPJLaineKOlkkolaKTEffect of inhibition of cytochrome P450 enzymes 2D6 and 3A4 on the pharmacokinetics of intravenous oxycodone: a randomized, three-phase, crossover, placebo-controlled studyClin Drug Investig2011313143153
   Web of Science ®Google Scholar
• GrönlundJSaariTIHagelbergNMNeuvonenPJOlkkolaKTLaineKExposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 aloneBr J Clin Pharmacol2010701788720642550
   PubMed Web of Science ®Google Scholar
• Noehr-JensenLZwislerSTLarsenFSindrupSHDamkierPBrosenKEscitalopram is a weak inhibitor of the CYP2D6-catalyzed O-demethylation of (+)-tramadol but does not reduce the hypoalgesic effect in experimental painClin Pharmacol Ther200986662663319710642
   PubMed Web of Science ®Google Scholar
• SnijdelaarDGKorenGKatzJEffects of perioperative oral amantadine on postoperative pain and morphine consumption in patients after radical prostatectomy: results of a preliminary studyAnesthesiology2004100113414114695734
   PubMed Web of Science ®Google Scholar
• Bujak-GiżyckaBKąckaKSuskiMBeneficial effect of amantadine on postoperative pain reduction and consumption of morphine in patients subjected to elective spine surgeryPain Med201213345946522313516
   PubMed Web of Science ®Google Scholar
• VachharajaniNNShyuWCNicholaPSBoultonDWA pharmacokinetic interaction study between butorphanol and sumatriptan nasal sprays in healthy subjects: importance of the timing of butorphanol administrationCephalalgia200222428228712100090
   PubMed Web of Science ®Google Scholar
• ManaraARShellyMPQuinnKParkGRThe effect of metoclopramide on the absorption of oral controlled release morphineBr J Clin Pharmacol19882545185213382595
   PubMed Web of Science ®Google Scholar
• HagelbergNMSaarikoskiTSaariTITiclopidine inhibits both O-demethylation and renal clearance of tramadol, increasing the exposure to it, but itraconazole has no marked effect on the ticlopidine-tramadol interactionEur J Clin Pharmacol201369486787523099620
   PubMed Web of Science ®Google Scholar
• NieminenTHHagelbergNMSaariTISt John’s wort greatly reduces the concentrations of oral oxycodoneEur J Pain201014885485920106684
   PubMed Web of Science ®Google Scholar
• LiukasAHagelbergNMKuusniemiKNeuvonenPJOlkkolaKTInhibition of cytochrome P450 3A by clarithromycin uniformly affects the pharmacokinetics and pharmacodynamics of oxycodone in young and elderly volunteersJ Clin Psychopharmacol201131330230821508859
   PubMed Web of Science ®Google Scholar
• GrönlundJSaariTHagelbergNEffect of telithromycin on the pharmacokinetics and pharmacodynamics of oral oxycodoneJ Clin Pharmacol201050110110819755414
   PubMed Web of Science ®Google Scholar
• VevelstadMPettersenSTallaksenCBrørsOO-demethylation of codeine to morphine inhibited by low-dose levomepromazineEur J Clin Pharmacol200965879580119308365
   PubMed Web of Science ®Google Scholar
• GelotSNakhlaEOpioid dosing in renal and hepatic impairmentUS Pharm20143983438
   Google Scholar
• IbrahimAEFeldmanJKarimAKharaschEDSimultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanilAnesthesiology200398485386112657846
   PubMed Web of Science ®Google Scholar